Amylyx Pharmaceuticals, Inc.
$15.94
The Read: Amylyx’s stock showed modest gains after Q4 2025 earnings landed between bear and bull targets, but then dropped about 12% after Q1 2026 results met EPS estimates yet raised investor concerns over cash runway and trial funding.
Price
Overlays
Panel
AMLX
Hover to view data
No Data